DR info

臨床試験数 : 15 / 薬物数 : 54 - (DrugBank : 34) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 141

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

6-Mercaptopurine
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 2   NCT00514982   United States;
Abatacept
   Emory University
      2014   Phase 1   NCT01917708   United States;
Adalimumab
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 2   NCT00514982   United States;
Alefacept
   Emory University
      2010   -   NCT01319851   United States;
Alemtuzumab
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
Allogeneic Bone Marrow Transplantation
   Fairview University Medical Center
      2000   -   NCT00006054   United States;
Allogeneic hematopoietic stem cell transplantation
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
Anti-thymocyte globulin
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
Anti-thymocyte globulin (ATG)
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00176865   United States;
Busulfan
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
Campath 1H
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00176865   United States;
Corticosteroids
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 2   NCT00514982   United States;
Cyclophosphamide
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
Cyclosporin A
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00176865   United States;
Cyclosporine
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
Erythromycin
   National Human Genome Research Institute (NHGRI)
      2007   Phase 1/Phase 2   NCT00467831   United States;
Etoposide
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
Filgrastim
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
Fludarabine
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00176865   United States;
Fludarabine phosphate
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
Infliximab
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 2   NCT00514982   United States;
Intravenous immunoglobulin (IVIG)
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00176865   United States;
Levodopa/carbidopa
   University of Wisconsin, Madison
      2012   Phase 2   NCT01663935   United States;
Losartan
   National Human Genome Research Institute (NHGRI)
      2007   Phase 1/Phase 2   NCT00467831   United States;
Lutein plus Zeaxanthin
   Johns Hopkins University
      2014   -   NCT02200263   United States;
Melphalan
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
      2002   Phase 2   NCT00176865   United States;
Mesalamine
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 2   NCT00514982   United States;
Methotrexate
   Fairview University Medical Center
      2000   -   NCT00006056   United States;
      2000   -   NCT00006054   United States;
Methylprednisolone
   Fairview University Medical Center
      2000   -   NCT00006054   United States;
Mycophenolate mofetil
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00176865   United States;
Myeloablative conditioning regimen
   Masonic Cancer Center, University of Minnesota
      2000   Phase 2/Phase 3   NCT00176826   United States;
N-Acetylcysteine
   National Human Genome Research Institute (NHGRI)
      2007   Phase 1/Phase 2   NCT00467831   United States;
Nitisinone
   National Eye Institute (NEI)
      2013   Phase 1/Phase 2   NCT01838655   United States;
Pirfenidone
   Jesse Roman
      2019   Phase 2   NCT04193592   Puerto Rico;United States;
   William Gahl, M.D.
      2005   Phase 2   NCT00001596   Puerto Rico;United States;
Pravastatin
   National Human Genome Research Institute (NHGRI)
      2007   Phase 1/Phase 2   NCT00467831   United States;
Prednisone
   Fairview University Medical Center
      2000   -   NCT00006054   United States;
Stem Cell Transplant
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2   NCT00176865   United States;
      2000   Phase 2/Phase 3   NCT00176826   United States;
Stem Cell Transplantation
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States;
Tacrolimus
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 2   NCT00514982   United States;
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
   Washington University School of Medicine
      2013   Phase 2   NCT01821781   United States;
Zileuton
   National Human Genome Research Institute (NHGRI)
      2007   Phase 1/Phase 2   NCT00467831   United States;